AVODART(Dutasteride) Post-marketing Surveillance(PMS) (AVO PMS)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Benign Prostatic Hyperplasia; Prostatic Hyperplasia

Treatments: Drug: Dutasteride

Study type: Observational

Funder types: Industry

Identifiers

NCT01299571

105194

Details and patient eligibility

About

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information

Enrollment: 3,977 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• The Korean BPH Patients administrated dutasteride according to the prescribing information

Exclusion criteria

• women and children and adolescents.
• patients with hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any of the excipients.

Trial design

3,977 participants in 1 patient group

Dutasteride

Description:

Patients administrated dutasteride at the site

Treatment:

Drug: Dutasteride